Cancer-focused biotechnology company eFFECTOR went public in late August through a combination with blank-check company Locust Walk Acquisition Corp.
Stockholders include Pfizer Inc., which owned 5.5% at the time of a recent securities filing. Pfizer and eFFECTOR announced a collaboration agreement in January 2020 to develop inhibitors of eIF4E.